Table 1.
Median and interquartile range of SARS-CoV-2 IgGS antibody test results in study participants with or without previous SARS-CoV-2 infection. Circulating levels of SARS-CoV-2 anti-spike (S) protein IgG (IgGS) antibodies in serum samples were evaluated monthly for 7 months after the second dose of the vaccine (Pfizer-BioNTech, BNT162b2 mRNA COVID-19).
| Time after Second Vaccine Dose |
Previously Infected Participants | Uninfected Participants |
p-Value |
|---|---|---|---|
| 1 month | 20,160.0 (8572.4; 32,247.2) |
8386.2 (4015.3; 13,374.1) |
<0.001 |
| 2 months | 9196.4 (4197.1; 21,490.9) |
4159.7 (2170.9; 6205.3) |
<0.001 |
| 3 months | 5357.6 (2830.2; 9806.7) |
2582.2 (1285.3; 4692.4) |
<0.001 |
| 4 months | 3837.8 (2100.1; 9051.9) |
1459 (785.9; 2789.9) |
<0.001 |
| 5 months | 2442.5 (1678; 5282.0) |
1160.3 (591.5; 1990.9) |
<0.001 |
| 6 months | 1855.7 (1234.3; 3462.6) |
870.7 (480.8; 1566.1) |
<0.001 |
| 7 months | 1501.4 (916.4; 2743.0) |
632.4 (385; 1151.8) |
<0.001 |